Reauthorizing the FDA’s user fee program, which allows the agency to decide how much to charge pharmaceutical and medical device-maker companies for their product submissions, was added to a spending bill Sept. 22 to prevent a government shutdown, according to The Hill.
Read the full post on Becker's Hospital Review - Healthcare News
